Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time 18, 2025 -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical comp

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept Atavistik Bio anticipates initiating its clinical trial in HHT in the first half of 2026 Dec. 18, 2025 -- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today an

$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 Dec. 19, 2025 -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovativ

Dec. 18, 2025 -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Series A represents an important

Dec. 16, 2025 -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 12,607,487 of the Company’s American Depositary Shares (“ADSs”) or ADS equivalents in lieu thereof, each representing 2,000 ordinary shares. In addition, the Company has agreed to issue unregistered warrants to purchase an agg

Dec. 15, 2025 -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Pursuant to the terms of the securities purchase agreement, Jade i

Dec. 15, 2025 -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deduct

Financing led by 5AM Ventures, OrbiMed, and Monograph Capital to drive development of a broad portfolio of proprietary obesity programs with potential for monthly and quarterly dosing; Founder Daniel Santi, M.D., Ph.D., transitions to Chief Technical and Scientific Officer role Dec. 11, 2025 -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced the closing of a $70 million Series A

Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital Management LLC and Vivo Capital Dec. 10, 2025 -- Blosso

$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran Eric Shaff appointed CEO and joins established leadership team, including Woody Sherman, Ph.D., Founder and Chief Innovation Officer, and Camil Sayegh, Ph.D., Chief Scientific Officer PsiThera’s scientific approach and QUAISAR™ platform, integrating molecular dynamics with artifi